Clinuvel Reports Positive Results in Stroke Treatment Study

An announcement from Clinuvel Pharmaceuticals Limited ( (AU:CUV) ) is now available.

Clinuvel Pharmaceuticals has announced positive preliminary results from its CUV803 study, which investigates the use of afamelanotide in treating arterial ischaemic stroke (AIS) patients. The study demonstrated that afamelanotide was well tolerated, with mild and transient adverse events, and showed functional improvement in 88.9% of patients and radiological improvement or stability in 66.7% of patients. These findings suggest potential benefits for AIS patients who are ineligible for standard treatments, although Clinuvel has decided to suspend further work in this area to focus on other therapeutic developments.

More about Clinuvel Pharmaceuticals Limited

Clinuvel Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing treatments for severe skin disorders and related conditions. The company is known for its work with afamelanotide, a drug designed to protect skin and other tissues from damage, and is exploring its use in treating conditions like vitiligo and porphyrias.

YTD Price Performance: -6.83%

Average Trading Volume: 459

Technical Sentiment Signal: Buy

Current Market Cap: $374.6M

Find detailed analytics on CUV stock on TipRanks’ Stock Analysis page.